Evidence map›Paper›PMID 41404114›Full record

ArticleFrontiers in allergy2025

Dietary 3'-sialyllactose reduces sensitization and type 2 inflammation in a house dust mite induced acute allergic asthma model.

M Zuurveld, J W M de Kleer, I van Ark, A Leusink-Muis, A I Kostadinova, J Garssen, G Folkerts, B Van't Land, L E M Willemsen

Abstract read
In one paragraph

Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M ZuurveldDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
J W M de KleerDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
I van ArkDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
A Leusink-MuisDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
A I KostadinovaDanone Research and Innovation, Utrecht, Netherlands.
J GarssenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
G FolkertsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
B Van't LandDanone Research and Innovation, Utrecht, Netherlands.
L E M WillemsenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Allergic asthma affects over 300 million people globally, characterized by a type 2 immune response to allergens like house dust mite (HDM). This includes eosinophilia, IgE production, and symptoms such as bronchial hyperresponsiveness. Human milk oligosaccharides (HMOS), ingested by breastfed infants, have immunomodulatory effects and may help prevent allergic diseases, like asthma. Methods: This study investigates the effects of two sialylated HMOS, 3'-sialyllactose (3'SL) and 6'-sialyllactose (6'SL), in a murine model of HDM-induced allergic asthma. Male BALB/c mice (6-7 weeks old) were fed an AIN93G diet with or without 0.1% or 0.5% 3'SL or 6'SL from 2 weeks before HDM sensitization until sacrifice. Airway hyperresponsiveness was measured after the final HDM challenge, and broncho-alveolar lavage fluid (BALF) and lung tissue were collected for analysis. Results: Dietary 0.5% 3'SL, 0.1% 6'SL, or 0.5% 6'SL prevented methacholine-induced airway hyperresponsiveness in HDM-challenged mice compared to control diet. Mice fed the 0.5% 3'SL diet had elevated SCFA levels in cecum content. Both 3'SL and 6'SL groups showed reduced HDM-induced macrophage influx in BALF. Mice on 3'SL diets had lower total inflammatory cell influx, while those on 0.5% 6'SL had increased eosinophils in BALF, associated with higher IL33, TNFα, CCL5, IFNγ levels, and reduced regulatory T cells. The 3'SL diets also prevented increases in HDM-specific IgE and mMCP1 in serum. Conclusion: Dietary 3'SL and 6'SL showed dose-dependent, differential clinical and immunological outcomes in HDM-sensitized mice. Both 0.5% 3'SL, 0.1% 6'SL, and 0.5% 6'SL reduced airway hyperresponsiveness. However, 0.5% 6'SL increased eosinophilic inflammation, while 3'SL protected against HDM-induced sensitization and asthma development.

Indexed as

allergic asthmaallergy preventionhuman milk oligosaccharidesimmunomodulationsialylated oligosaccharides

Identifiers

PMID41404114
PMCPMC12702718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.